A61K 38/1777
Integrin superfamily
Official title: {Integrin superfamily}
A61K38/1777 (Integrin superfamily) appears on 34 US grants and 70 published applications in this corpus.
Search patents in A61K- Granted patents
- 34
- Published applications
- 70
- Assignees
- 48
- Inventors
- 144
- Latest grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 3 |
| 2003 | 0 | 2 |
| 2004 | 0 | 1 |
| 2005 | 1 | 4 |
| 2006 | 1 | 2 |
| 2007 | 1 | 1 |
| 2008 | 0 | 3 |
| 2009 | 1 | 2 |
| 2010 | 2 | 1 |
| 2011 | 0 | 2 |
| 2012 | 3 | 1 |
| 2013 | 0 | 1 |
| 2014 | 1 | 2 |
| 2015 | 2 | 2 |
| 2016 | 2 | 3 |
| 2017 | 2 | 3 |
| 2018 | 1 | 5 |
| 2019 | 1 | 3 |
| 2020 | 2 | 6 |
| 2021 | 3 | 8 |
| 2022 | 2 | 3 |
| 2023 | 2 | 3 |
| 2024 | 4 | 2 |
| 2025 | 1 | 5 |
| 2026 | 1 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Fusion protein for targeted thrombolysis for treatment of microvascular thrombosis26 May 2026US 12,636,351 B2TargED Biopharmaceuticals B.V.
- VEGFR fusion protein pharmaceutical composition3 Jun 2025US 12,318,428 B2Allgenesis Biotherapeutics Inc.
- Compositions and methods for treatment of GCase related disease states5 Nov 2024US 12,133,880 B2Children's Hospital Medical Center
- Fused in sarcoma (FUS) nuclear translocation inhibitors for preventing fibrosis13 Aug 2024US 12,060,396 B2The United States AS Represented By the Department of Veterans Affairs
- Methods for treating multidrug resistant breast cancer16 Jul 2024US 12,037,361 B2The Hong Kong Polytechnic University
- Method for Treating Ulcerative Colitis or Primary Sclerosing Cholangitis16 Jul 2026US 2026/0199576 A1Kyoto University
- Identification of highly immunosupresive treg population in tumor microenvironments12 Mar 2026US 2026/0069694 A1The Trustees of Columbia University in the City of New York
- Vegfr fusion protein pharmaceutical composition16 Oct 2025US 2025/0319157 A1Allgenesis Biotherapeutics Inc.
- Targeted thrombolysis for treatment of microvascular thrombosis7 Aug 2025US 2025/0249082 A1UMC Utrecht Holding B.V.
- Modified integrin polypeptides, modified integrin polypeptide dimers, and uses thereof26 Jun 2025US 2025/0206802 A1Children's Medical Center Corporation
Most cited
By later US patents
- Method for enhancing or inhibiting insulin-like growth factor-I9US 7,723,483 B2The University of North Carolina at Chapel Hill · 2010
- Modified integrin polypeptides, modified integrin polypeptide dimers, and uses thereof7US 10,273,283 B2Children's Medical Center Corporation · 2019
- Method for enhancing or inhibiting insulin-like growth factor-I7US 8,206,706 B2The University of North Carolina at Chapel Hill · 2012
- Alpha(v)beta(6) integrin-binding peptides and methods of use thereof3US 11,185,601 B2The Regents of the University of California · 2021
- Method for inhibiting pulmonary oxygen toxicity3US 5,310,551 ABoehringer Ingelheim Pharmaceuticals, Inc. · 1994